Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 13/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | OGA | O60502 | 2/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011974 | 0.87 | FAAH (0.54) | FAAHCYP3A4CYP2D6GABRA1ADRA2C | |
| SCHEMBL27094605 | 0.87 | FAAH (0.51) | FAAHCYP3A4CYP2D6GABRA1ADRA2C | |
| SCHEMBL30657588 | 0.87 | FAAH (0.51) | FAAHCYP3A4CYP2D6GABRA1ADRA2C | |
| SCHEMBL27209671 | 0.86 | GPR119 (0.49) | FAAHCYP3A4CYP2D6GABRA1ADRA2C | |
| SCHEMBL27094609 | 0.83 | CYP3A4 (0.49) | FAAHCYP3A4CYP2D6GABRA1ADRA2C | |
| SCHEMBL27209649 | 0.83 | FAAH (0.45) | FAAHCYP3A4CYP2D6GABRA1ADRA2C | |
| SCHEMBL30903847 | 0.82 | EPHX2 (0.49) | FAAHCYP3A4CYP2D6GABRA1ADRA2C | |
| SCHEMBL1012253 | 0.81 | MGAM (0.48) | OGA | |
| SCHEMBL27094839 | 0.81 | CYP3A4 (0.57) | FAAHCYP3A4CYP2D6GABRA1ADRA2C | |
| SCHEMBL1011754 | 0.80 | FAAH (0.53) | FAAHCYP3A4CYP2D6GABRA1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140930-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROPN THERAPEUTICS INC. (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240139172-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NeuroPn Therapeutics, Inc. (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2024073648-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NeuroPn Therapeutics, Inc. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073680-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROPN THERAPEUTICS INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139172-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | PDCD1, TP53, CHEK2 | FAAH 3812/4885CYP3A4 3768/4885CYP2D6 4456/4885 |
| US-20240140930-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | PRPH, EPHX1, BCHE | FAAH 15/4885CYP3A4 2031/4885CYP2D6 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.